Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Epidermolysis Bullosa - Market Insight, Epidemiology, and Market Forecast - 2034
... (EBS) is the least severe type of epidermolysis bullosa, and many individuals with EBS may experience improvements as they age. On the other hand, recessive dystrophic epidermolysis bullosa is considered the most critical. Among the ... Read More
-
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034
... on healthcare systems and patient care. In 2023, among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Alzheimer’s disease, representing 30% of the total cases, followed by France (24%). ... Read More
-
Impetigo Drugs
... CAGR of 4.4% over the analysis period 2024-2030. Fusidane Drug, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$883.5 Million by the end of the analysis ... Read More
-
Osteoarthritis Therapeutics
... CAGR of 7.3% over the analysis period 2024-2030. Knee, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.1 Billion by the end of the analysis period. ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Women's Health Therapeutics
... at a CAGR of 12.9% over the analysis period 2024-2030. Postmenopausal Osteoporosis, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$18.1 Billion by the end of ... Read More
-
Multiple Sclerosis Drugs
... at a CAGR of 6.7% over the analysis period 2024-2030. Immmunomoderator Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$13.2 Billion by the end of ... Read More
-
Radiodermatitis
... 4.2% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$412.0 Million by the end of the analysis period. Growth in ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
... reach US$57.7 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Stimulant, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$47.7 ... Read More
-
Huntington`s Disease Therapeutics
... at a CAGR of 31.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 40.0% CAGR The Huntington`s Disease Therapeutics market in the U.S. ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the end ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis period. ... Read More
-
Cloud-Based Drug Discovery Platforms
... 2030, growing at a CAGR of 14.3% over the analysis period 2024-2030. Pharmaceutical Vendors End-Use, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$3.0 Billion by ... Read More
-
Cystic Fibrosis Therapeutics
... at a CAGR of 15.2% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$42.1 Billion by the end of the ... Read More
-
Gastroesophageal Reflux Disease (GERD) Therapeutics
... Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.6 Billion by ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Organs-on-Chips
... 35.3% over the analysis period 2024-2030. Liver, one of the segments analyzed in the report, is expected to record a 36.6% CAGR and reach US$206.0 Billion by the end of the analysis period. Growth in ... Read More
-
Peptide Therapeutics
... CAGR of 4.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$29.9 Billion by the end of the analysis period. ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
Research Assistance
